Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (16)

« Back to Publications

Self-monitoring of blood pressure following a stroke or transient ischaemic attack (TASMIN5S): a randomised controlled trial.

McManus RJ. et al, (2024), BMC Cardiovasc Disord, 24

Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial.

Sheppard JP. et al, (2024), Lancet Healthy Longev, 5, e563 - e573

Effect of antihypertensive deprescribing on serious adverse events, mortality, and cardiovascular disease: Long-term follow-up of the OPTiMISE randomised controlled trial

Sheppard J. et al, (2024), The Lancet Healthy Longevity

Effect of antihypertensive deprescribing on serious adverse events, mortality, and cardiovascular disease: Long-term follow-up of the OPTiMISE randomised controlled trial

Sheppard J. et al, (2024), Journal of Hypertension, 42, e109 - e110

Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial.

Kyle SD. et al, (2023), Lancet, 402, 975 - 987

Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial

Kyle S. et al, (2023), The Lancet, 402, 975 - 987

Informed consent in randomised controlled trials: further development and evaluation of the participatory and informed consent (PIC) measure.

Wade J. et al, (2023), Trials, 24

SHORT-TERM SAFETY OF ANTIHYPERTENSIVE MEDICATION REDUCTION IN MULTI-MORBID PATIENTS WITH MILD HYPERTENSION: THE OPTIMISE RANDOMISED CONTROLLED NON-INFERIORITY TRIAL

Sheppard J. et al, (2021), Journal of Hypertension, 39, e369 - e370

OPTIMAL DRUGS FOR MEDICATION REDUCTION: SECONDARY ANALYSIS OF THE OPTIMISE MEDICATION REDUCTION TRIAL

Sheppard J. et al, (2021), Journal of Hypertension, 39, e52 - e52

Generalizability of Blood Pressure Lowering Trials to Older Patients: Cross-Sectional Analysis.

Sheppard JP. et al, (2020), J Am Geriatr Soc, 68, 2508 - 2515

Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients aged ≥ 80 years with hypertension

Sheppard J. et al, (2020), JAMA: Journal of the American Medical Association

andomised controlled trial of blood pressure self-monitoring in the management of hypertensive pregnancy. OPTIMUM-BP: A feasibility trial.

Pealing LM. et al, (2019), Pregnancy Hypertens, 18, 141 - 149

Self-monitoring blood pressure in hypertensive pregnancies: the OPTIMUM-BP pilot randomised-controlled trial

Pealing L. et al, (2019), BJOG: An International Journal of Obstetrics and Gynaecology, 126

Do these data apply to me? Examining the applicability of trials assessing strategies for optimal management of blood pressure to older patients in UK primary care

Sheppard J. et al, (2019), EUROPEAN HEART JOURNAL, 40, 1604 - 1604

OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial.

Sheppard JP. et al, (2018), BMJ Open, 8

Load More